Study Name	Year	Study code	Reference	Trial Duration in months	RA disease duration in years	Intervention	Comparator
ABATACEPT
Moreland	2002	A0001	Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion. Arthritis and Rheumatism. 2002 Jun;46(6):1470‐9.	3	3.3	ABA	PL
Genovese	2005	A0002	Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. New England Journal of Medicine. 2005 Sep 15;353(11):1114‐23	6	11.9	ABA + DMARD	DMARD + PL
Schiff	2008	A0003	Schiff MH, Pritchard C, Huffstutter JE, Rodriguez‐Valverde V, Durez P, Zhou X, et al. The 6‐month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti‐TNF therapy or were directly switched to abatacept: the ARRIVE trial. Annals of the Rheumatic Diseases. 2008 Dec 15.	6	8.1	ABA + MTX	MTX + PL
Kremer	2003	A0004	Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T‐cell activation with fusion protein CTLA4Ig. New England Journal of Medicine. 2003 Nov 13;349(20):1907‐15.	6	9.2	ABA + MTX	MTX + PL
Kremer	2006	A0005	Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud‐Mendoza C, et al. Effects of abatacept in patients with methotrexate‐resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine. 2006 Jun 20;144(12):865‐76.	12	8.6	ABA + MTX	MTX + PL
Weinblatt	2007	A0006	Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Annals of the Rheumatic Diseases. 2007 Feb;66(2):228‐34.	12	12.9	ABA + ETN	ETN + PL
Weinblatt (ASSURE)	2006	A0007	Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: A one‐year randomized, placebo‐controlled study. Arthritis Rheum. 2006 Sep;54(9):2807‐16..	12	9.7	ABA + DMARD(biologic + non‐biologic)	DMARD(biologic + non‐biologic) + PL
ADALIMUMAB
Bejarano	2008	A0008	Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al. Effect of the early use of the anti‐tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis and Rheumatism. 2008 Oct 15;59(10):1467‐74.	13	0.9	ADA + MTX	MTX + PL
Breedveld	2006	A0009	Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis and Rheumatism. 2006 Jan;54(1):26‐37.	24	0.7	ADA + MTX	MTX + PL
Furst	2003	A0010	Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor‐alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). The Journal of Rheumatology. 2003 Dec;30(12):2563‐71.	6	10.4	ADA + DMARD	DMARD + PL
Keystone	2004	A0011	Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti‐tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo‐controlled, 52‐week trial. Arthritis and Rheumatism. 2004 May;50(5):1400‐11.	12	11.0	ADA + MTX	MTX + PL
Kim	2007	A0012	Kim H, Lee S, Song Y, Yoo D, Koh EM, Yoo B, et al. A randomized, double‐blind, placebo‐controlled, phase III study of the human anti‐tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR Journal of Rheumatology. 2007;10:9‐16.	6	6.8	ADA + MTX	MTX + PL
Miyasaka	2008	A0013	Miyasaka N. Clinical investigation in highly disease‐affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Modern Rheumatology. 2008;18(3):252‐62.	6	9.8	ADA	PL
Van de Putte	2004	A0014	van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Annals of the Rheumatic Diseases. 2004 May;63(5):508‐16.	6	11.1	ADA	PL
Weinblatt	2003	A0015	Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti‐tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and Rheumatism. 2003 Jan;48(1):35‐45.	6	11.7	ADA + MTX	MTX + PL
ANAKINRA
Bresnihan	1998	A0016	Bresnihan B, Alvaro‐Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin‐1 receptor antagonist. Arthritis and Rheumatism. 1998 Dec;41(12):2196‐204.	6	4.1	ANA	PL
Fleischiman	2003	A0017	Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo‐controlled trial. Arthritis and Rheumatism. 2003 Apr;48(4):927‐34.	6	10.3	ANA + DMARD	PL + DMARD
Cohen	2002	A0018	Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: results of a twenty‐four‐week, multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism. 2002 Mar;46(3):614‐24.	6	7.8	ANA + MTX	MTX + PL
Cohen	2004	A0019	Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Annals of the Rheumatic Diseases. 2004 Sep;63(9):1062‐8.	6	10.5	ANA + MTX	MTX + PL
Genovese	2004	A0020	Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis and Rheumatism. 2004 May;50(5):1412‐9.	6	10.2	ANA + ETN +MTX	ETN + MTX + PL
ETANERCEPT
Moreland	1999	A0021	Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Annals of Internal Medicine. 1999 Mar 16;130(6):478‐86.	6	11.5	ETA	PL
Weinblatt	1999	A0022	Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine. 1999 Jan 28;340(4):253‐9.	6	13.0	ETA + MTX	MTX + PL
Emery (COMET)	2008	A0023	Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double‐blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675‐81.	12	0.9	ETA + MTX	MTX + PL
Klareskog (TEMPO)	2004	A0024	Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double‐blind, parallel treatment trial. Lancet. 2008 Aug 2;372(9636):375‐82.	12	6.8	ETA + MTX	MTX + PL
INFLIXIMAB
Maini	1998	A0025	Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti‐tumor necrosis factor alpha monoclonal antibody combined with low‐dose weekly methotrexate in rheumatoid arthritis. Arthritis and Rheumatism. 1998 Sep;41(9):1552‐63.	6	9.9	INF + MTX	MTX + PL
St. Clair (ASPIRE)	2004	A0026	St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and Rheumatism. 2004 Nov;50(11):3432‐43.	12	0.8	INF + MTX	MTX + PL
Lipsky (ATTRACT)	2000	A0027	Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti‐Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. New England Journal of Medicine. 2000 Nov 30;343(22):1594‐602.	12	10.5	INF + MTX	MTX + PL
Quinn	2005	A0028	Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor‐prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve‐month randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism. 2005 Jan;52(1):27‐35.	12	0.7	INF + MTX	MTX + PL
RITUXIMAB
Edwards	2004	A0029	Edwards JC, Szczepanski L, Szechinski J, Filipowicz‐Sosnowska A, Emery P, Close DR, et al. Efficacy of B‐cell‐targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine. 2004 Jun 17;350(25):2572‐81.	6	11.5	RIT + MTX	MTX + PL
Emery (DANCER)	2006	A0030	Emery P, Fleischmann R, Filipowicz‐Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial. Arthritis and Rheumatism. 2006 May;54(5):1390‐400.	6	10.1	RIT + MTX	MTX + PL
Cohen (REFLEX)	2006	A0031	Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti‐tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks. Arthritis and Rheumatism. 2006 Sep;54(9):2793‐806.	6	11.9	RIT + MTX	MTX + PL